This Week in Mathematical Oncology
This week in
Mathematical Oncology
December 26, 2017 ~ Issue 2
From the editor
A main theme of today's issue is cancer therapy scheduling. One paper discusses the null model for synergistic effects in the combination of drugs (i.e. independent action), while a rebuttal advocates for better metrics (best response or duration of response) to tease apart confounding effects.
Math models have much to contribute to the understanding of collateral sensitivity -- and therapy scheduling optimizations in general. We've included some of our favorite preprints and publications below (and even a blog post).
We've also included a review discussing the differences in the terms precision and personalized medicine. It's a fascinating review of the implications of each term that ends in a pitch for a new term: individualized medicine.
-Jeffrey West
#MathOnco Publications
Nominalism in medicine:
the case of personalized or precision medicine
Authors: Italo Portioli
Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy
Authors: Adam C. Palmer, Peter K. Sorger
On the design of combination cancer therapy
Authors: James H. Doroshow, Richard M. Simon
Chemotherapeutic dose scheduling based on tumor growth rates provides a case for low-dose metronomic high-entropy therapies
Authors: Jeffrey West, Paul K. Newton
Modeling the subclonal evolution of cancer cell populations
Authors: Diego Chowell, James Napier, ..., Melissa A Wilson Sayres
Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment
Authors: Thomas D. Gaddy, Qianhui Wu, Alyssa D. Arnheim, Stacey D. Finley
#MathOnco Preprints
Optimal therapy scheduling based on a pair of collaterally sensitive drugs
Authors: Nara Yoon, Robert Vander Velde, Andriy Marusyk, Jacob Scott
PhysiCell: an open source physics-based cell simulator for 3-D multicellular systems
Authors: Ahmadreza Ghaffarizadeh, Randy Heiland, ..., Paul Macklin
Extended logistic growth model for heterogeneous populations
Authors: Wang Jin, Scott McCue, Matthew Simpson
Size matters: metastatic cluster size and stromal recruitment in the establishment of successful prostate cancer to bone metastases
Authors: Arturo Araujo, Leah Cook, Conor Lynch, David Basanta
Mathematical models for cell migration with real-time cell cycle dynamics
Authors: Sean T Vittadello, Scott McCue, ..., Matthew Simpson
Modeling acute myeloid leukemia in a continuum of differentiation states
Authors: Heyrim Cho, Kimberly Ayers, ..., Russell C. Rockne
#MathOnco blogs
Estimating the minimal time on PD-1/PD-L1 inhibitors for successful tumor regression
"Without a doubt, introducing immune checkpoint inhibitors to the clinic was a major breakthrough in the war against cancer. However, despite spectacular successes, therapies based on checkpoint inhibitors still suffer from relatively low response rates. I will show how the variability in the observed response dynamics is explained by the model and how can we estimate the minimal time on PD-1/PD-L1 treatment required for a therapeutical success." (Jan Poleszczuk)
#MathOnco Books
One Renegade Cell: How Cancer Begins
As director of the Oncology Research Laboratory at the Whitehead Institute and professor of Biology (MIT), Weinberg delivers a well-written short introduction to the field of cancer. The length (pocket-sized) makes it an ideal read for over the holidays!
The Emperor of All Maladies: A Biography of Cancer
In this substantially longer volume, written as a biography of the disease, Siddhartha Mukherjee details an extensive and well-researched background to the history of cancer research. Poignant and easy to read, you won't want to put this one down.
Do you see something we missed? Click the submit button below to send us an idea for next week's issue.
The #MathOnco newsletter is maintained by @jeffreyjizzle. If you were forwarded this email, subscribe for free to get it delivered every week.